GLP-1 Receptor Agonists Found Effective for Weight Loss Among Adults Without Diabetes

Since there is a lack of head-to-head trials on these agents, future research should explore their comparative efficacy (e.g. semaglutide vs. tirzepatide vs. retatrutide).

WeightControl.com Interview with:

Areesha Moiz BSc
Centre of Clinical Epidemiology, Lady Davis Institute
Jewish General Hospital, and Division of Experimental Medicine
McGill University, Montreal, Quebec, Canada
Division of Experimental Medicine
McGill University

WeightControl.com:  What is the background for this study? 

Response: GLP-1 receptor agonists have been used for type 2 diabetes management for almost two decades. Trials conducted in this patient population also showed some weight loss effects, leading to them being investigated in patients with overweight or obesity and without diabetes. With all the recent buzz around Ozempic (semaglutide) these past few years, we were interested in seeing what other agents in this class of drugs were out there, how they performed for weight loss, and how safe they were. 

Last Updated on January 13, 2025 by weightcontrol

Pages: Page 1, Page 2